NAD+ Research: From the Salvage Pathway to the Human Trials

Start here

This page maps NAD+ research in three moves: where NAD+ comes from, what consumes it, and what happened when people actually took its precursors in trials. The recurring theme is a gap between two things that are easy to confuse. Raising NAD+ in the blood is well proven. Producing the downstream benefits people want from it — better metabolism, more energy, slower aging — is far less proven in humans. Keep the NAD+-versus-precursor distinction in mind throughout: when a study says participants 'took NMN' or 'took NR', they took a precursor (a building block the body turns into NAD+), not NAD+ itself.

How NAD+ precursors raise NAD+ (salvage and Preiss-Handler routes)

NAD+ is synthesized through several conserved routes, and knowing which one a precursor uses explains a lot about how it behaves. The dominant route in mammals is the salvage pathway, which recycles nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT (nicotinamide phosphoribosyltransferase) and then NMNAT ^[5]. NR enters by a different door: the kinases NRK1 and NRK2 convert it to NMN, which then proceeds to NAD+ — a route that sidesteps the Preiss-Handler pathway ^[5]. Niacin (nicotinic acid) feeds NAD+ through that Preiss-Handler pathway, and tryptophan supplies a slow de novo route conserved from bacteria to humans ^[11].

The pathways are not sealed off from one another, and that matters for supplements. A 2023 study showed that gut bacteria can deamidate orally administered NMN into nicotinic acid mononucleotide, rerouting a portion of dietary NMN into the Preiss-Handler pathway rather than the expected salvage route ^[9]. A 2026 trial confirmed the same theme: ex vivo fermentation showed the microbiome converts both NR and NMN to nicotinic acid, implicating gut bacteria as a real variable in how strongly any individual responds to an oral precursor ^[14].

NMN (nicotinamide mononucleotide), a direct NAD+ precursor

NMN sits just one biochemical step from NAD+, which makes it a direct precursor, and oral NMN raises blood NAD+ in human trials. A 2023 randomized, multicenter, double-blind trial in healthy middle-aged adults tested 300, 600 and 900 mg/day for 60 days; blood NAD+ rose significantly at days 30 and 60 across all NMN groups versus placebo (p≤0.001), walking distance improved, and the trial identified 600 mg/day as the optimal dose with no safety issues at any level ^[3]. In a separate trial, 10 weeks of NMN at 250 mg/day improved muscle insulin sensitivity in prediabetic, postmenopausal women without changing body weight or HbA1c ^[1].

NMN's regulatory status is the unsettled part. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug — a marketplace dispute over how NMN may be sold, not a finding that NMN is unsafe or 'banned'. That status is covered as part of NAD+ safety and side effects.

Nicotinamide riboside (NR), the most clinically studied oral NAD+ booster

NR is the most clinically studied oral NAD+ precursor, and its dose-response is the clearest in the literature. A randomized, double-blind, placebo-controlled trial in healthy overweight adults gave NR at 100, 300 or 1000 mg/day for eight weeks and measured whole-blood NAD+ rising by 22%, 51% and 142% respectively — a clean dose-dependent effect maintained throughout the study ^[4]. The same trial found NR did not cause flushing, did not elevate LDL cholesterol, and did not disrupt one-carbon (methyl-donor) metabolism, with no significant adverse-event difference from placebo at any dose ^[4].

A 2026 head-to-head trial sharpened the comparison: over 14 days, both NR and NMN roughly doubled whole-blood NAD+ versus placebo (differences of about 49 and 43 µM respectively, p<0.001), while plain nicotinamide had no significant effect — useful evidence that not every B3-family compound moves NAD+ equally ^[14].

NAD+ vs NMN: the coenzyme and its precursor

The cleanest way to hold the distinction: NAD+ is the working coenzyme; NMN is one of the building blocks the body converts into it. They are not interchangeable, and the difference is practical, not pedantic. Oral NAD+ itself is poorly taken up by most cells intact — an in vitro study of human fibroblasts found extracellular NAD is broken down by surface enzymes to nicotinamide, NMN and purine fragments before anything is taken in, with adenosine the main product actually absorbed ^[12]. That is precisely why precursors such as NMN and NR are the rational oral approach: they are absorbable forms that the cell's own machinery then assembles into NAD+ ^[3][4]. When a label or a headline says 'NAD+', the active ingredient by mouth is almost always a precursor.

The NAD+-consuming enzymes: sirtuins, PARPs, and CD38

NAD+ is spent, not merely used, and three enzyme families do most of the spending. Sirtuins (SIRT1-7) are NAD+-dependent deacylases that regulate metabolism, stress resistance and DNA repair ^[5]. PARP1 is a DNA-repair enzyme that consumes large quantities of NAD+ when DNA damage activates it ^[5]. CD38 is an NAD-consuming ectoenzyme that rises with age and inflammation ^[10].

CD38 is the one that ties the field together. A 2016 study established CD38 as the principal NAD+-consuming enzyme whose activity climbs with age, driving the age-related fall in tissue NAD+; CD38-knockout mice were protected against that decline, preserving NAD+ and SIRT3 activity and improving mitochondrial function with age ^[2]. Because these enzymes compete for a shared NAD+ pool, the foundational reviews frame restoring NAD+ as a candidate strategy against age-related disease — while being careful to call it a candidate, not a settled therapy ^[5].

What NAD+ research has shown — and the open questions

Two results are robust. First, oral NMN and NR reliably and dose-dependently raise blood NAD+ ^[3][4][14]. Second, a few trials show real functional gains, most notably improved muscle insulin sensitivity with NMN ^[1]. Beyond that, the record is candid about its own limits. A 2023 review of NAD+-boosting trials confirmed safety across compounds and doses but found most functional endpoints unchanged despite reliable NAD+ elevation, and concluded that the optimal dose, duration and target population remain unknown ^[7]. A 2025 Nature Metabolism review reached a parallel verdict for ageing specifically: limited human efficacy and sparse tissue-NAD+ data ^[13]. Newer interest in areas such as fertility is mostly preclinical and not established in human trials ^[13]. The honest summary is that the pharmacology is solid and the clinical payoff is unresolved.

Does NAD help with fertility?

Fertility is an area of newer, mostly preclinical interest within NAD+ research and is not an established human benefit in the cited trials. The most current authoritative synthesis — a 2025 Nature Metabolism review — emphasizes that human efficacy data across endpoints remain limited ^[13].

Does NAD help with weight loss?

Weight loss is not an established outcome in the cited human trials; reviews of NMN and NR studies report no consistent improvement in body composition or energy expenditure despite reliable NAD+ elevation ^[7]. One NMN trial improved muscle insulin sensitivity without changing body weight ^[1].

Do NAD patches work?

Transdermal patches and other non-oral consumer formats (sublingual, intranasal, topical) are marketed but have little controlled evidence; the bulk of rigorous human data is for oral precursors ^[7]. The cited literature does not establish that NAD+ patches raise NAD+ meaningfully.